Selicrelumab ( Investigational drug (no approved brand names); Generic name: Selicrelumab )

Immunotherapy

Experimental

Not available 1 Clinical Trials

Description

Selicrelumab is an investigational immunotherapy drug currently being studied in clinical trials for certain types of colorectal cancer. It is being investigated as a potential treatment option for metastatic colorectal cancer (mCRC) that has not responded to standard first- and second-line therapies. The drug is being tested in combination with other cancer treatments, including other immunotherapies and targeted therapies, to see if these combinations are safe and effective. It is important to note that selicrelumab is not yet approved for use in colorectal cancer and is only available as part of clinical trials.

Mechanism of Action

Selicrelumab is designed to target a specific protein involved in immune regulation. By targeting this protein, the drug aims to enhance the body's own immune system's ability to recognize and attack cancer cells. The specific protein target and detailed mechanism of action are still being characterized in ongoing clinical trials.

Side Effects

As an investigational drug The full range of side effects for selicrelumab is still being evaluated in clinical trials. Information from the NCT03555149 trial indicates that side effects are being closely monitored as part of the safety assessment. Common side effects associated with immunotherapy drugs in general can include fatigue Rash Diarrhea Nausea And infusion-related reactions. Specific side effects related to selicrelumab will become clearer as more data becomes available from clinical trials.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT03555149 Phase 1

Archived

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)

United States, Australia, France, South Korea, Switzerland

Quick Info

Brand Name	Investigational drug (no approved brand names); Generic name: Selicrelumab
Category	Immunotherapy
EMA Status	Experimental
Spain Access	Not available
Clinical Trials	1

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.

Selicrelumab (** Investigational drug (no approved brand names); Generic name: Selicrelumab **)